Altered expression profile of BAFF receptors on peripheral blood B lymphocytes in Graves’ Disease

Xin Wang  
Jiangsu Province Hospital of TCM/the Affiliated Hospital of Nanjing University of Chinese Medicine

Jinhui Huang  
Jiangsu Province Hospital of TCM/the Affiliated Hospital of Nanjing University of Chinese Medicine

Aixia Zhang  
Nanjing Medical University

Chen Fang  
Second Affiliated Hospital of Soochow University

Qi Ma  
Second Affiliated Hospital of Soochow University

Penjun Jiang (✉ endotcm@163.com)  
Jiangsu Province Hospital of TCM/the Affiliated Hospital of Nanjing University of Chinese Medicine

Research article

Keywords: Graves’ disease, Hashimoto’s thyroiditis, BAFF, BR3, TACI,

Posted Date: November 6th, 2020

DOI: https://doi.org/10.21203/rs.3.rs-33595/v2

License: © This work is licensed under a Creative Commons Attribution 4.0 International License.  Read Full License

Version of Record: A version of this preprint was published at BMC Endocrine Disorders on April 29th, 2021. See the published version at https://doi.org/10.1186/s12902-021-00752-3.
Abstract

Background: B lymphocyte activating factor (BAFF) is a growth factor regulating B lymphocytes survival and maturation. Serum BAFF levels were elevated in patients affected with autoimmune thyroid diseases (AITD), including Graves’ disease (GD) and Hashimoto’s thyroiditis (HT). The aim of this study is to investigate the association of expression of BAFF receptors on the peripheral blood B lymphocytes in addition to serum BAFF concentrations in patients affected with GD.

Methods: Fifty-two GD patients, 39 Hashimoto’s thyroiditis (HT) patients and 23 healthy controls (HC) were recruited in this study. Serum BAFF levels and its receptors expression, including BAFF receptor 3 (BR3) and transmembrane activator and calcium-modulating and cyclophilin ligand interactor (TACI), in AITD patients were compared to those in HC. In 10 patients with Graves’ orbitopathy (GO) receiving steroids therapy, effects of steroids on serum BAFF levels and expression of BR3 and TACI were observed.

Results: Serum BAFF levels were significantly elevated from 0.93 ± 0.24 ng/ml in HC to 1.18 ± 0.33 ng/ml in GD (P =0.0027) and 1.02 ± 0.24 ng/ml in HT (P =0.0331). BR3 expression on peripheral B lymphocytes were elevated in GD (mean MFI: 4.52 ± 2.06 in GD vs 3.00 ± 0.87 in HC, P =0.0015), while TACI expression on peripheral B lymphocytes were decreased in GD without significance (mean MFI: 7.96 ± 4.06 in GD vs 9.10 ± 3.37 in HC, P =0.1285). Expression of BR3 and TACI was not changed significantly in HT patients. Steroids significantly suppressed serum BAFF concentrations (from 1.18 ± 0.27 ng/ml to 0.97 ± 0.10 ng/ml, P =0.0364) and BR3 expression in GO patients (mean MFI from 6.26 ± 4.91 to 4.05 ± 1.58, P =0.0083).

Conclusions: Altered expression of BAFF and its receptor may mediate the autoimmunity in GD. Restoring the normal expression profile of receptors for BAFF could be a new strategy to treat GD.

Introduction

Graves’ disease (GD) is an autoimmune disease characterized by the presence of the thyrotropin receptor specific autoantibody (TRAb)[1]. The TRAb binds to the thyrotropin receptor with agonistic properties and stimulate the over production of thyroid hormone [1]. The production of autoantibodies is a result of aberrant activated autoreactive B lymphocytes. B cell activation factor (BAFF) is a typical B lymphocytes co-stimulation molecule promote autoreactive B lymphocytes activation. These autoantibodies are secreted from the defective autoreactive B lymphocytes. Under normal conditions, these autoreactive B lymphocytes are eliminated or in an inactivated state which was called anergy. In autoimmune diseases as GD, these defective autoreactive B lymphocytes survive and are activated [1].

The aberrant activation of autoreactive B lymphocytes could be induced by excess production of B cell activating factor (BAFF, also known as Blys). BAFF provides B lymphocytes with essential survival signals [2]. Because its ability to rescue low-affinity autoreactive transitional B lymphocytes at tolerance checkpoints and promote their maturation [2,3], BAFF has long been linked to autoimmune diseases. Overexpression of BAFF in mice induced a dramatic expansion of activated autoreactive B lymphocytes and autoantibody production [4]. In humans, serum BAFF levels are elevated in autoimmune diseases including systemic lupus erythematosus (SLE) [5], autoimmune hepatitis [6] and primary Sjögren’s syndrome [7].

Accumulated evidences suggest BAFF is involved in the pathogenesis of autoimmune thyroid diseases (AITD). BAFF gene polymorphisms have been linked to the susceptibility to GD [8,9]. Serum BAFF levels are elevated in
patients affected with AITD [10-12]. BAFF was also shown to affect the occurrence of thyroid autoimmunity in chronic hepatitis C patients receiving interferon alpha therapy [13]. Blocking BAFF activity by soluble BAFF receptor-Fc fusion protein relieved hyperthyroidism in a murine model [14]. Finally, steroids improve Graves’ orbitopathy (GO) through inhibiting BAFF secretion [12].

BAFF has three cell surface receptors: BAFF receptor 3 (BR3, CD268; also known as TNFRSF13C) [15], transmembrane activator and calcium-modulating and cyclophilin ligand interactor (TACI, CD267; also known as TNFRSF13B) [16] and B cell maturation antigen (BCMA; also known as TNFRSF17) [17]. The three receptors for BAFF have different expression profiles based on B cell developmental stages [3,18]. As the dominant BAFF receptor, BR3 is expressed on almost all B lymphocytes that express functional B cell receptor (BCR), including naïve B cells, marginal zone B cells and switched memory B cells. TACI is mainly expressed by CD27+ memory B cells and a small part of plasma cells. Expression of BCMA is restricted on plasmablasts and plasma cells. Campi et al. found that expression of BAFF and BR3 in thyroid infiltrating lymphocytes (TIL) in AITD was higher than that of multinodular goiter [19]. However, it is not clear how the expression of BAFF receptors on peripheral blood B lymphocytes changes in the context of GD.

In the present study, to investigate whether the expression of different BAFF receptors on peripheral blood cells was associated with the autoimmunity of GD, we measured serum BAFF levels and expression of two BAFF receptors, BR3 and TACI, on the peripheral blood B lymphocytes in GD patients. Furthermore, their changes after steroids therapy in patients affected with GO were also observed.

**Materials And Methods**

**Power Calculation and Patients**

Power was calculated by R package. We set the Type I Error=0.05 and the Type II Error=0.2. Based on the data of our initial assay, at least 14 subjects should be enrolled. Indeed 52 newly diagnosed GD patients, 39 HT patients and 23 healthy controls (HC) were recruited from Jiangsu Province Hospital of TCM/the Affiliated Hospital of Nanjing University of Chinese Medicine. All the GD patients were in hyperthyroidism state. In the HT group, 29 patients were euthyroidic, 5 patients were with subclinical hypothyroidism and the remaining 5 patients were clinical hyperthyroidic.

**Therapy**

All GD patients received methimazole therapy. Initial methimazole dosage was determined by serum free tetraiodothyronine concentration according to the American thyroid association (ATA) guideline for management for hyperthyroidism [20]. Ten patients having clinical activity score (CAS) above 3/7 at the first examination were diagnosed with active GO according to the European Group of Graves' Orbitopathy (EUGOGO) classification system [21]. These patients underwent methylprednisolone iv injection in addition to administration of methimazole. Methylprednisolone was administered 500mg weekly in the first 6 weeks and 250 mg weekly in the following 6 weeks as Zhu et al. described [22].

**Thyroid function and thyroid autoantibodies assay**

Thyroid function, including serum thyroid stimulating hormone (TSH), free thyroxine (FT4) and free triiodothyronine (FT3) levels, and TRAb titers, were measured by Roche Elecys electrochemiluminescence
immunoassay (ECL) kit. Thyroid peroxidase autoantibody (TPOAb) was assayed by ECL kit from Beckman Coulter.

**BAFF ELISA**

Serum BAFF concentrations were determined by the Quantikine ELISA kit (R&D systems, DBLYS0B). The sensitivity of the kit was 2.68 pg/ml. The intra-assay coefficient of variation of the kit was 5.6%. All the samples were measured duplicate. Blank and serially diluted recombinant BAFF from 4,000 pg/ml to 62.5 pg/ml were assayed at the same time to establish standard curve. Concentration of BAFF in each sample was calculated according to the formula deducted from the standard curve.

**Cell Staining and Flow Cytometry**

Peripheral blood mononuclear cells (PBMC) were isolated from 5ml fresh anti-coagulated blood by lymphoprep (StemCell Technologies) and blocked with FcR blocking buffer (Miltenyi Biotec, cat number: 130-059-901) at 4˚C for 10 minutes in the dark. Cells were then stained with fluorescein isothiocyanate (FITC) conjugated anti human CD19 (thermosher, cat number: 11-0199-42) with either phycoerythrin (PE) conjugated anti human BR3 (thermosher, cat number: 12-9117-42) or PE conjugated anti human TACI (thermosher, cat number: 12-9217-42) at 4˚C for 30 minutes in the dark. Cells were acquired on a Navios flow cytometer (Beckman, U.S.). Data were analyzed by using Kaluza Flow Cytometry Analysis Software Version 2.0 (Beckman, U.S.). For each test, at least 50,000 PBMCs were acquired. Mean fluorescent intensity (MFI) of e BR3 and TACI on CD19+ cells were determined. Data are represented as Mean ± SD.

**Statistics**

Statistical analysis was performed by Graphpad Prism Version 6.0. One-way ANOVA and t-test were applied to compare serum BAFF concentrations, MFI of BR3 or TACI among groups. Correlations were analyzed by Spearman's rank correlation tests. A P value less than 0.05 was considered statistically significant.

**Results**

1. **Subjects characteristics**

Characteristics of the patients and controls were listed in Table 1.

2. **Elevated serum BAFF levels in patients affected with AITD**

Serum BAFF levels were elevated in autoimmune diseases including GD in previous studies. To confirm these findings, we measured serum BAFF concentrations in both AITD patients and healthy controls by ELISA. As shown in Figure 1, serum BAFF levels were significantly higher in patients with either GD (1.18 ± 0.33 ng/ml, P=0.0027) or HT (1.02±0.24, P=0.0331) than those in healthy controls (0.93 ± 0.24 ng/ml, Figure1). BAFF concentrations did not differ between euthyroid patients and hypothyroid patients in HT group (data were not shown).

Despite previous studies showed serum BAFF levels were associated with activity of autoimmune, there were inconsistent results on the correlations between BAFF expression levels and autoantibodies titers. We thus investigated whether serum BAFF levels correlated with either thyroid function or thyroid autoantibodies titers in AITD patients. As shown in Table 2, serum BAFF levels positively correlated with serum free thyroxine concentrations (Spearman r = 0.2460, P = 0.0394), but not the TRAb titers (P = 0.4734) in GD patients. However,
serum BAFF concentrations were associated with TPOAb titers in both GD (R=0.2451, P=0.0399, Table 2) and HT (R=0.2983, P=0.0325, Table 2). There was no correlation between sera BAFF levels and free thyroxine concentrations in HT (P=0.2655, Table 2).

3. Altered expression profile of receptors for BAFF on peripheral blood B lymphocytes in Graves’ disease

BAFF receptors include BR3, TACI and BCMA. Because BCMA expression is restricted on plasma cells and plasmablasts, both of them exist at extremely low frequencies in peripheral blood, we only measured BR3 and TACI expression in this study. Most of CD19+ cells express BR3 while only part of B lymphocytes express TACI. The percentages of TACI-expressing B lymphocytes were comparable between healthy controls and GD patients (data were not shown). Expression levels of BR3 on peripheral blood B lymphocytes in GD patients were higher than that in healthy controls (mean MFI: 4.52 ± 2.06 in GD vs 3.00 ± 0.87 in HC, P=0.0015, Figure 2A). However, expression of TACI was decreased in GD patients without statistical significance (mean MFI: 7.96 ± 4.06 in GD vs 9.10 ± 3.37 in HC, P=0.1285, figure 2B). No difference of BR3 and TACI expression between HT patients and controls was observed (figure 2B). These data suggested altered expression of BAFF receptors on peripheral blood B lymphocytes in GD patients.

4. Altered expression of BAFF receptors was corrected by steroids in GO

Steroids have been shown to suppress serum BAFF concentrations in GO patients, however, their effects on expression of BAFF receptors have not been studied. We therefore analyzed serum BAFF concentrations, expression levels of BR3 and TACI on peripheral blood B lymphocytes before and at the end of steroids therapy in 10 GO patients. At baseline, serum BAFF levels and BAFF receptors expression did not differ between GO group and non-GO group (data were not shown). Mean serum BAFF concentrations were decreased from 1.18 ± 0.27 ng/ml at baseline to 0.97 ± 0.10 ng/ml (P=0.0364, Table 3) at the end of methylprednisolone therapy. BR3 expression on peripheral blood B lymphocytes in GO patients was reduced (MFI was decreased from 6.26 ± 4.91 at baseline to 4.05 ± 1.58 at the end of therapy, P=0.0083, Table 3). TACI expression in B lymphocytes after steroids therapy was increased without statistical significance (MFI 6.67 ± 1.96 at baseline vs 7.05 ± 2.32 after steroids therapy, P=0.1974, Table 3). These results indicated immunosuppressive effect of steroids on B lymphocytes was not only on the B cell surviving factor BAFF, but also on its receptors, mainly BR3.

Discussion

In the present study, we observed elevated serum BAFF concentrations in patients affected with AITD. In addition, expression of BAFF receptors BR3 was increased on the peripheral B lymphocytes in GD patients. Steroids suppressed both BAFF expression and BR3 expression in GO patients.

Our data showed elevated serum BAFF levels in GD patients, in line with other studies describing increased serum BAFF levels in AITD [10,12]. A potential role of BAFF in the occurrence of GD was supported by the investigation that blockade of BAFF through a BAFF specific receptor-Fc fusion protein improved hyperthyroidism in a murine model. There was no association between serum BAFF levels and TRAb titers in this study. A possible explanation of this result is TRAbs measured in this study were antibodies with specific epitope as monoclonal antibody M22, but not the whole TRAb repertoire in the sera. Indeed, we have found serum BAFF concentrations correlate positively with TPOAb titers in both GD and HT, an evidence to support BAFF is associated with autoimmunity in
AITD. Serum BAFF levels also correlated with free thyroxine concentrations in GD. Because over secretion of thyroxine is driven by TRAb in GD, our results indicate BAFF is important in TRAb production in GD.

There was an altered expression profile of BAFF receptors on peripheral blood B lymphocytes in GD patients in this study: BR3 expression was increased while TACI expression was reduced without significance. BR3 expression on B lymphocytes was reduced in SLE patients but was increased in thyroid infiltrating lymphocytes in patients suffering from AITD [19]. Different results of TACI expression on peripheral B lymphocytes in SLE patients have been reported [5,15]. The inconsistency indicates expression profiles of BAFF receptors may vary in different autoimmune diseases or disease status. [15]. BR3 and TACI oppositely regulate B cell homeostasis [2,16,23], BR3 promotes B cells survival while TACI sensitizes B cells to apoptosis [23]. TACI also controls activity of B regulatory lymphocytes (Bregs) [16,24], a subtype of B lymphocytes with immunosuppressive function. Loss of Bregs has been described in GD patients [25]. Therefore, the altered expression of BAFF and its receptors may mediate autoimmunity by enhancing BR3 signal pathway activity and inhibiting TACI signal pathway activity [2, 26-27]. Unbiased blockade of both BR3 and TACI signal pathways will only augment inflammation due to decreased IL-10 secretion, as observed in multiple sclerosis (MS) patients [24]. To selective inhibit the BR3 signal pathway and to restore the TACI signal pathway could be a better strategy to cue GD. The expression levels of BR3 and TACI on peripheral blood B lymphocytes did not differ significantly between patients diagnosed with HT and healthy controls. Possible explanation is HT is a T lymphocyte mediated autoimmune disease, the autoreactive B lymphocytes might impact the occurrence of the disease through an indirect effect.

The present study showed expression of BAFF was suppressed by steroids, consistent with previous studies. BR3 expression levels were decreased after steroids therapy. In large B cell lymphoma, BR3 rather than BAFF was an independent prognostic factor for steroids treatment [28]. Therefore, BR3 is an important target of steroids in B lymphocytes. Due to the small sample size of patients receiving steroids, the effect of steroids on TACI expression need be studied in the future with a larger sample size.

Conclusions

In conclusions, altered expression of BAFF receptors was associated with autoimmunity of GD. Restoring the expression profile of BAFF receptors could be a new strategy to treat and cue GD.

Abbreviations

APRIL: a proliferation-inducing ligand

AITD: autoimmune thyroid diseases

ATA: American Thyroid Association

BAFF: B lymphocyte activating factor

BR3: BAFF receptor 3

BCMA: B cell maturation antigen

BCR: B cell receptor
Declarations

Ethic approval and consent to participate

This study was in accordance with the Helsinki declaration of 1975, as revised in 2008 and approved by Institutional Review Board (IRB) of the Affiliated Hospital of Nanjing University of Chinese Medicine. Written informed consent was obtained from all participants.

Consent for publication

Not applicable.
Availability of data and material

The datasets generated during and/or analyzed during the current study are available from the corresponding authors on reasonable request.

Declarations

Competing interests

The authors declare that they have no conflict of interest.

Funding

This study was sponsored by Natural Science Foundation of Jiangsu Province (Grant number: BK20181502), National Natural Science Foundation of China (Grant number: 81100555), Subject of Academic Priority Discipline of Jiangsu Higher Education Institutions (Grant number: ZYX03KF063) to X.W.

Authors’ contributions

X.W., Q.M. and P.J. contributed to data analysis, manuscript drafting and critical discussion. X.W., J.H. collected the samples. X.W. and P.J. performed flow cytometer assay. A.Z. performed the ELISA assay.

References

1. Giuliani C, Cerrone D, Harii N et al. (2012) A TSHR-LH/CGR chimera that measures functional thyroid-stimulating autoantibodies (TSAb) can predict remission or recurrence in Graves’ patients undergoing antithyroid drug (ATD) treatment. J Clin Endocrinol Metab. 97:E1080-E1087
2. Seshasayee D VP, Yan M, Dixit Vm, Tumas D, Grewal Is (2003) Loss of TACI causes fatal lymphoproliferation and autoimmunity, establishing TACI as an inhibitory BLyS receptor. Immunity. 18:279-288
3. Chang SE, Guo L, Tian J et al. (2012) Autoimmune bone marrow environment severely inhibits B cell development by inducing extensive cell death and inhibiting proliferation. Autoimmunity 45:210-217
4. De Leo S, Lee SY, Braverman LE (2016) Hyperthyroidism. Lancet 388:906-918
5. Ferraccioli G, Gremese E (2017) B cell activating factor (BAFF) and BAFF receptors: fakes and facts. Clinical & Experimental Immunology 190:291-292
6. Migita K, Abiru S, Maeda Y et al. (2007) Elevated serum BAFF levels in patients with autoimmune hepatitis. Hum Immunol 68:586-591
7. Nocturne G, Mariette X (2018) B cells in the pathogenesis of primary Sjogren syndrome. Nat Rev Rheumatol 14:133-145
8. Lane LC, Allinson KR, Campbell K et al. (2019) Analysis of BAFF gene polymorphisms in UK Graves’ disease patients. Clinical Endocrinology 90:170-174
9. Lin JD, Yang SF, Wang YH et al. (2016) Analysis of Associations of Human BAFF Gene Polymorphisms with Autoimmune Thyroid Diseases. PLoS One. 11:e015443671
10. Fabris M, Grimaldi F, Villalta D et al. (2010) BLyS and April serum levels in patients with autoimmune thyroid diseases. Autoimmunity Reviews 9:165-169
11. Lin JD, Wang YH, Fang WF et al. (2016) Serum BAFF and thyroid autoantibodies in autoimmune thyroid disease. Clin Chim Acta 462:96-102
12. Vannucchi G, Covelli D, Curro N et al. (2012) Serum BAFF concentrations in patients with Graves' disease and orbitopathy before and after immunosuppressive therapy. J Clin Endocrinol Metab 97:E755-759
13. Kajiyama Y, Kikuchi K, Takai A et al. (2012) B-Cell-Activating Factor Affects the Occurrence of Thyroid Autoimmunity in Chronic Hepatitis C Patients Treated with Interferon Alpha. Clinical and Developmental Immunology 2012:1-4
14. Gilbert JA, Kalled SL, Moorhead J et al. (2006) Treatment of autoimmune hyperthyroidism in a murine model of Graves' disease with tumor necrosis factor-family ligand inhibitors suggests a key role for B cell activating factor in disease pathology. Endocrinology 147:4561-4568
15. Khan WN, Wright JA, Kleiman E et al. (2013) B-lymphocyte tolerance and effector function in immunity and autoimmunity. Immunol Res 57:335-353
16. Saulep-Easton D, Vincent FB, Quah PS et al. (2016) The BAFF receptor TACI controls IL-10 production by regulatory B cells and CLL B cells. Leukemia 30:163-172
17. Salazar-Camarena DC, Ortiz-Lazareno PC, Cruz A et al. (2016) Association of BAFF, APRIL serum levels, BAFF-R, TACI and BCMA expression on peripheral B-cell subsets with clinical manifestations in systemic lupus erythematosus. Lupus
18. Pieper K, Grimbacher B, Eibel H (2013) B-cell biology and development. J Allergy Clin Immunol 131:959-971
19. Campi I, Tosi D, Rossi S et al. (2015) B Cell Activating Factor (BAFF) and BAFF Receptor Expression in Autoimmune and Nonautoimmune Thyroid Diseases. Thyroid. 25:1043-1049.
20. Ross DS, Burch HB, Cooper DS et al. (2016) American Thyroid Association Guidelines for Diagnosis and Management of Hyperthyroidism and Other Causes of Thyrotoxicosis. Thyroid. 26:1343-1421.
21. Perros P, Hegedus L, Bartalena L et al. (2017) Graves' orbitopathy as a rare disease in Europe: a European Group on Graves' Orbitopathy (EUGOGO) position statement. Orphanet J Rare Dis 12:72
22. Zhu W, Ye L, Shen L et al. (2014) A prospective, randomized trial of intravenous glucocorticoids therapy with different protocols for patients with graves' ophthalmopathy. J Clin Endocrinol Metab 99:1999-2007
23. Salazar-Camarena DC, Ortiz-Lazareno PC, Cruz A et al. (2016) Association of BAFF, APRIL serum levels, BAFF-R, TACI and BCMA expression on peripheral B-cell subsets with clinical manifestations in systemic lupus erythematosus. Lupus. 25:582-592.
24. Hua C, Audo R, Yeremenko N et al. (2016) A proliferation inducing ligand (APRIL) promotes IL-10 production and regulatory functions of human B cells. J Autoimmun 73:64-72
25. Ji X, Wan J, Chen R et al. (2020) Low frequency of IL-10-producing B cells and high density of ILC2s contribute to the pathological process in Graves' disease, which may be related to elevated-TRAb levels. Autoimmunity 53:78-85
26. Vincent FB, Saulep-Easton D, Figgett WA et al. (2013) The BAFF/APRIL system: Emerging functions beyond B cell biology and autoimmunity. Cytokine & Growth Factor Reviews 24:203-215
27. Zhang Y, Li J, Zhang Y-M et al. (2015) Effect of TACI Signaling on Humoral Immunity and Autoimmune Diseases. Journal of Immunology Research 2015:1-12
28. Wang Y, Li YJ, Jiang WQ et al. (2015) Expression of BAFF-R, but not BAFF, is an independent prognostic factor in diffuse large B-cell lymphoma patients treated with R-CHOP. Ann Hematol 94:1865-1873
**Tables**

**Table 1. Characteristics of the subjects in the study**

| Group | n  | Gender M/F | Age (±11.53) | TRAb (IU/L) | TPOAb (IU/L) | TSH (mIU/L) | FT3 (pg/ml) | FT4 (ng/dl) | Methimazole (mg) |
|-------|----|------------|---------------|-------------|--------------|-------------|-------------|-------------|------------------|
| GD    | 52 | 18/34      | 36.46±11.53   | 179.18±253.26 | 0.16±0.41    | 6.17±4.97   | 1.88±1.35   | 14.71±8.37   |
| HT    | 39 | 12/27      | 37.89±15.59   | 221.62±317.05 | 5.55±9.80    | 3.2±0.67    | 0.86±0.17   | N.A.           |
| HC    | 23 | 12/11      | 39.96±12.14   | <1.75        | <3.5         | N.A.        | N.A.        | N.A.          |

TRAb: thyrotropin receptor autoantibody; TPOAb: thyroid peroxidase autoantibody; TSH: thyroid stimulating hormone; FT3: free triiodothyronine; FT4: free thyroxine; GD: Graves’ disease; HT: Hashimoto’s thyroiditis; FT4: free thyroxine

**Table 2. Correlations between serum BAFF concentrations and thyroid autoantibodies and thyroid hormones in AITD**

| Component | GD | HT |
|-----------|----|----|
| TRAb      | 0.147 | 0.2451 |
| TPOAb     | 0.2983 | 0.2460 |

**Table 3. Effect of steroids treatment on BAFF and its receptors expression in GO patients**
|               | GO baseline | Steroids therapy | P    |
|---------------|-------------|------------------|------|
| BAFF (ng/ml)  | 1.18±0.27   | 0.97±0.10*       | 0.0364 |
| R3 MFI        | 6.26±4.91   | 4.05±1.58*       | 0.0083 |
| ACl MFI       | 6.67±1.96   | 7.05±2.32        | 0.1974 |

**Figures**

**Figure 1**

Increased serum BAFF levels in AITD patients. Serum BAFF levels were elevated in GD patients (1.183 ± 0.334 ng/ml) and HT patients (1.02±0.24) comparing with healthy controls (0.934 ± 0.238 ng/ml). AITD: autoimmune...
thyroid disease; HC: healthy controls; GD: Graves’ disease; HT: Hashimoto's thyroiditis; Bars: mean BAFF levels; ns: not significant; *: vs HC, P<0.05, **: vs HC, P<0.01.

Figure 2

Altered expression profile of receptors of BAFF on peripheral blood B lymphocytes in GD. (A): Elevated BR3 expression on peripheral blood B lymphocytes in GD patients. Mean MFI of BR3 on peripheral B lymphocytes in GD patients was 4.52 ± 2.06, higher than that in HC (3.00 ± 0.87), P=0.0015; BR3 expression in HT patients was not increased; (B): Trend of decreased TACI expression on peripheral B lymphocytes in GD patients. Mean MFI of TACI on peripheral B lymphocytes in GD patients was 7.96 ± 4.06, lower than that in HC (9.10 ± 3.37) without significance, P =0.1285. TACI expression in HT was not decreased. MFI: mean fluorescence intensity. Bars: mean MFI. ns: not significant; **: vs HC, P<0.01.

Supplementary Files

This is a list of supplementary files associated with this preprint. Click to download.

- STROBEchecklistBAFFRGD.docx